XBIOTECH INC (XBIT) Stock News

USA - Nasdaq - NASDAQ:XBIT - CA98400H1029 - Common Stock

2.55 USD

-0.01 (-0.39%)

Last: 12/11/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

XBIT Latest News, Press Relases and Analysis

All

Press Releases

10 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT

a year ago - By: The Schall Law Firm

XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm

a year ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT

a year ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT

a year ago - By: XBiotech Inc.

XBiotech setzt Rheumatologieprogramm aus

a year ago - By: XBiotech Inc.

XBiotech suspend son programme de rhumatologie

a year ago - By: XBiotech Inc.

XBiotech Pauses Rheumatology program

a year ago - By: BusinessInsider

News Image

XBIT Stock Earnings: XBiotech Reported Results for Q2 2024

a year ago - By: XBiotech Inc.

XBiotech Pauses Rheumatology program

a year ago - By: InvestorPlace

XBIT Stock Earnings: XBiotech Reported Results for Q2 2024

1 years ago - By: XBiotech Inc.

Ergebnisse aus randomisierter, doppelt verblindeter Phase-I/II-Studie von XBiotech deuten auf mögliche bahnbrechende Behandlung gegen fortgeschrittenen Bauchspeicheldrüsenkrebs hin

1 years ago - By: XBiotech Inc.

Les résultats de XBiotech d’une étude randomisée de phase 1/2 en double aveugle suggèrent l’émergence d’un traitement révolutionnaire potentiel contre le cancer du pancréas avancé

2 years ago - By: BusinessInsider

News Image

XBIT Stock Earnings: XBiotech Reported Results for Q1 2024

2 years ago - By: InvestorPlace

XBIT Stock Earnings: XBiotech Reported Results for Q1 2024

2 years ago - By: BusinessInsider

News Image

XBIT Stock Earnings: XBiotech Reported Results for Q4 2023

1 years ago - By: Benzinga

What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?

1 years ago - By: XBiotech Inc.

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

1 years ago - By: XBiotech Inc.

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

2 years ago - By: InvestorPlace

XBIT Stock Earnings: XBiotech Reported Results for Q4 2023

2 years ago - By: Benzinga - Mentions: AEMD TBIO SNTI OPGN ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

2 years ago - By: XBiotech Inc.

XBiotech beginnt mit dem Bau der neuen F&E-Anlage auf seinem 19 Hektar großen Campus

2 years ago - By: XBiotech Inc.

XBiotech entame la construction d’un nouveau centre de recherche et développement sur son campus de 19 hectares

2 years ago - By: XBiotech Inc.

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

2 years ago - By: XBiotech Inc.

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

2 years ago - By: XBiotech Inc.

Dr. Alan Kivitz leitet XBiotechs Natrunix-Programm für rheumatoide Arthritis

2 years ago - By: XBiotech Inc.

Le Dr Alan Kivitz prend la tête du programme Natrunix, conduit par XBiotech dans le traitement de la polyarthrite rhumatoïde

2 years ago - By: XBiotech Inc.

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

2 years ago - By: XBiotech Inc.

XBiotech meldet Abschluss der Rekrutierung von Teilnehmern in klinischer Phase-I-Studie zu Hutrukin, einem neuartigen Therapiekandidaten bei Schlaganfällen, bekannt

2 years ago - By: XBiotech Inc.

XBiotech annonce l'achèvement du recrutement dans son essai clinique de phase I concernant Hutrukin, un nouveau traitement candidat pour l'AVC

2 years ago - By: XBiotech Inc.

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

2 years ago - By: XBiotech Inc.

XBiotech gibt den Abschluss der Rekrutierung von Patient*innen für Phase II der placebokontrollierten, multizentrischen klinischen Studie zu Natrunix bei Bauchspeicheldrüsenkrebs bekannt

2 years ago - By: XBiotech Inc.

XBiotech annonce l'achèvement du recrutement concernant son étude multicentrique contrôlée par placebo de phase II pour Natrunix dans la lutte contre le cancer du pancréas

2 years ago - By: XBiotech Inc.

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

2 years ago - By: XBiotech Inc.

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

2 years ago - By: XBiotech Inc.

XBiotech annonce la première administration du nouveau traitement Natrunix à un patient lors d'un essai clinique de phase II sur l'arthrite rhumatoïde (AR)

2 years ago - By: XBiotech Inc.

XBiotech gibt ersten mit der neuartigen Natrunix-Therapie behandelten Patienten in einer klinischen Phase-II-Studie zu rheumatoider Arthritis (RA) bekannt

2 years ago - By: XBiotech Inc.

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

2 years ago - By: XBiotech Inc.

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial